US "Black box" warnings for metoclopramide-containing drugs
This article was originally published in Scrip
The US FDA has issued a requirement for all metoclopramide-containing medications to add a stronger "black box" warning to their labels about the risk of tardive dyskinesia with chronic use of the drugs.
You may also be interested in...
Allergan will pay $200m to exercise its option to buy Motus Therapeutics (formerly Rhythm Health) after what the pharma described as a successful Phase IIb study for relamorelin in diabetic gastroparesis.
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.